Literature DB >> 18588518

Adaptor protein Lnk associates with Tyr(568) in c-Kit.

Saskia Gueller1, Sigal Gery, Verena Nowak, Liqin Liu, Hubert Serve, H Phillip Koeffler.   

Abstract

The adaptor protein Lnk is expressed in haemopoietic cells and plays a critical role in haemopoiesis. Animal model studies demonstrated that Lnk acts as a broad inhibitor of signalling pathways in haemopoietic lineages. Lnk belongs to a family of proteins sharing several structural motifs, including an SH2 (Src homology 2) domain which binds phosphotyrosine residues in various signal-transducing proteins. The SH2 domain is essential for Lnk-mediated negative regulation of several cytokine receptors [e.g. Mpl, EpoR (erythropoietin receptor), c-Kit]. Therefore inhibition of the binding of Lnk to cytokine receptors might lead to enhanced downstream signalling of the receptor and thereby to improved haemopoiesis in response to exposure to cytokines (e.g. erythropoietin in anaemic patients). This hypothesis led us to define the exact binding site of Lnk to the stem cell factor receptor c-Kit. Pull-down experiments using GST (glutathione transferase)-fusion proteins of the different domains of c-Kit showed that Lnk almost exclusively binds to the phosphorylated juxtamembrane domain. Binding of Lnk to the juxtamembrane domain was abolished by point mutation of Tyr(568) and was competed by peptides with a phosphotyrosine residue at position 568. Co-immunoprecipitation with full-length wild-type or Y568F mutant c-Kit and Lnk confirmed these results, thus showing the importance of this phosphorylated tyrosine residue. Lnk bound directly to c-Kit without requiring other interacting partners. The identification of the binding site of Lnk to c-Kit will be useful to discover inhibitory molecules that prevent the binding of these two proteins, thus making haemopoietic cells more sensitive to growth factors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18588518     DOI: 10.1042/BJ20080102

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  11 in total

1.  Adaptor protein Lnk inhibits c-Fms-mediated macrophage function.

Authors:  Saskia Gueller; Helen S Goodridge; Birte Niebuhr; Hongtao Xing; Maya Koren-Michowitz; Hubert Serve; David M Underhill; Christian H Brandts; H Phillip Koeffler
Journal:  J Leukoc Biol       Date:  2010-06-22       Impact factor: 4.962

2.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

3.  Dasatinib impairs long-term expansion of leukemic progenitors in a subset of acute myeloid leukemia cases.

Authors:  Lina Han; Jan Jacob Schuringa; André Mulder; Edo Vellenga
Journal:  Ann Hematol       Date:  2010-04-13       Impact factor: 3.673

4.  Overexpression of Lnk in the Ovaries Is Involved in Insulin Resistance in Women With Polycystic Ovary Syndrome.

Authors:  Meihua Hao; Feng Yuan; Chenchen Jin; Zehong Zhou; Qi Cao; Ling Xu; Guanlei Wang; Hui Huang; Dongzi Yang; Meiqing Xie; Xiaomiao Zhao
Journal:  Endocrinology       Date:  2016-07-26       Impact factor: 4.736

5.  SH2B3 (LNK) mutations from myeloproliferative neoplasms patients have mild loss of function against wild type JAK2 and JAK2 V617F.

Authors:  Maya Koren-Michowitz; Sigal Gery; Takayuki Tabayashi; Dechen Lin; Rocio Alvarez; Arnon Nagler; H Phillip Koeffler
Journal:  Br J Haematol       Date:  2013-04-17       Impact factor: 6.998

6.  Adaptor protein Lnk binds to and inhibits normal and leukemic FLT3.

Authors:  De-Chen Lin; Tong Yin; Maya Koren-Michowitz; Ling-Wen Ding; Saskia Gueller; Sigal Gery; Takayuki Tabayashi; Ulla Bergholz; Julhash U Kazi; Lars Rönnstrand; Carol Stocking; H Phillip Koeffler
Journal:  Blood       Date:  2012-08-31       Impact factor: 22.113

7.  Octa-arginine mediated delivery of wild-type Lnk protein inhibits TPO-induced M-MOK megakaryoblastic leukemic cell growth by promoting apoptosis.

Authors:  Chung Yeng Looi; Miki Imanishi; Satoshi Takaki; Miki Sato; Natsuko Chiba; Yoji Sasahara; Shiroh Futaki; Shigeru Tsuchiya; Satoru Kumaki
Journal:  PLoS One       Date:  2011-08-10       Impact factor: 3.240

Review 8.  The role of small adaptor proteins in the control of oncogenic signalingr driven by tyrosine kinases in human cancer.

Authors:  Cécile Naudin; Clément Chevalier; Serge Roche
Journal:  Oncotarget       Date:  2016-03-08

9.  SRC-like adaptor protein 2 (SLAP2) is a negative regulator of KIT-D816V-mediated oncogenic transformation.

Authors:  Kaja Rupar; Sausan A Moharram; Julhash U Kazi; Lars Rönnstrand
Journal:  Sci Rep       Date:  2018-04-23       Impact factor: 4.379

10.  LNK (SH2B3): paradoxical effects in ovarian cancer.

Authors:  L-W Ding; Q-Y Sun; D-C Lin; W Chien; N Hattori; X-M Dong; S Gery; M Garg; N B Doan; J W Said; J-F Xiao; H Yang; L-Z Liu; X Meng; R Y-J Huang; K Tang; H P Koeffler
Journal:  Oncogene       Date:  2014-04-07       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.